# Vedolizumab for Immune Mediated Colitis

> **NCT04797325** · PHASE2 · UNKNOWN · sponsor: **University of Copenhagen** · enrollment: 82 (estimated)

## Conditions studied

- Immune-Mediated Colitis

## Interventions

- **DRUG:** Vedolizumab
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT04797325
- **Lead sponsor:** University of Copenhagen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-30
- **Primary completion:** 2025-04
- **Final completion:** 2025-04
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2022-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04797325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04797325, "Vedolizumab for Immune Mediated Colitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04797325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*